Population-based Genetic Testing for Precision Prevention.
Biomarkers, Tumor
/ genetics
Breast Neoplasms
/ diagnosis
Cost-Benefit Analysis
Counseling
/ economics
DNA Mutational Analysis
/ economics
Early Detection of Cancer
/ economics
Female
Genetic Predisposition to Disease
Genetic Testing
/ economics
Heterozygote
Humans
Jews
/ genetics
Mutation
Ovarian Neoplasms
/ diagnosis
Patient Education as Topic
/ economics
Precision Medicine
/ economics
Prevalence
Risk Assessment
/ economics
Journal
Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
01
01
2020
revised:
22
03
2020
accepted:
08
05
2020
pubmed:
16
5
2020
medline:
26
10
2021
entrez:
16
5
2020
Statut:
ppublish
Résumé
Global interest in genetic testing for cancer susceptibility genes (CSG) has surged with falling costs, increasing awareness, and celebrity endorsement. Current access to genetic testing is based on clinical criteria/risk model assessment which uses family history as a surrogate. However, this approach is fraught with inequality, massive underutilization, and misses 50% CSG carriers. This reflects huge missed opportunities for precision prevention. Early CSG identification enables uptake of risk-reducing strategies in unaffected individuals to reduce cancer risk. Population-based genetic testing (PGT) can overcome limitations of clinical criteria/family history-based testing. Jewish population studies show population-based
Identifiants
pubmed: 32409595
pii: 1940-6207.CAPR-20-0002
doi: 10.1158/1940-6207.CAPR-20-0002
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
643-648Informations de copyright
©2020 American Association for Cancer Research.